David Linden

MRI as a source for biomarker research

Professor Translational Neuroscience and Scientific Director of the School for Mental Health and Neuroscience (MHeNs) Maastricht University

David Linden read medicine, classics and philosophy in Germany. He completed a doctorate in functional neuroimaging at the Max Planck Institute for Brain Research and trained in psychiatry at Frankfurt University. He held academic appointments at Bangor and Cardiff Universities, UK and worked as a neuropsychiatrist in North Wales, at the Wales Brain Injury Service and the Welsh Huntington’s Disease Service. In 2017 he took up the post of scientific director of the School for Mental Health and Neuroscience at Maastricht University. He also works as a neuropsychiatrist at the Expertise Center Huntington’s Disease at Maastricht University Medical Center. Over the last ten years he has developed and evaluated clinical protocols for neurofeedback based on functional magnetic resonance imaging (MRI) and was the coordinator of the European BRAINTRAIN consortium (www.braintrainproject.eu). He also researches the relationship between genetic risk variants and mechanisms of neurodevelopmental and neurodegenerative disorders, using clinical phenotyping, neuroimaging, neurophysiology and, increasingly (and through collaboration with investigators in Cardiff and Maastricht) also cellular models and bioinformatics. He is the author of “The Biology of Psychological Disorders” (2nd edition, 2018), “Brain Control” (2014) and “Neuroimaging and Neurophysiology in Psychiatry” (2016).

Publications Prof. David Linden >

Abstract | MRI as a source for biomarker research
New developments in neuroimaging, particularly the unprecedented spatial resolution and signal strength afforded by ultra-high field MRI (7 Tesla and beyond), open up new opportunities for mechanistic investigations in Huntington’s disease (HD) and other neurodegenerative processes. I will review some recent advances in quantitative MRI and techniques that allow for the identification of pathophysiological processes, for example disruption of the blood brain barrier, and discuss the application in HD. I will also discuss the potential use of these techniques for the identification of biomarkers that allow us to track disease progression and document effects of disease-modifying treatments.